HUTCHMED (China) Limited (HCM)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
HUTCHMED (China) Limited (HCM) trades at $13.37 with AI Score 42/100 (Weak). HUTCHMED (China) Limited is a biopharmaceutical company focused on discovering, developing, and commercializing targeted therapeutics and immunotherapies, primarily in oncology and immunology. Market cap: 2414641186, Sector: Healthcare.
Last analyzed: Mar 15, 2026HUTCHMED (China) Limited (HCM) Healthcare & Pipeline Overview
HUTCHMED (China) Limited, a biopharmaceutical company based in Hong Kong, specializes in developing and commercializing targeted therapeutics and immunotherapies for cancer and immunological diseases. With a focus on oncology and immunology, the company boasts a diverse pipeline of drug candidates and strategic collaborations to drive growth in the global pharmaceutical market.
Investment Thesis
HUTCHMED (China) Limited presents a notable research candidate within the biopharmaceutical sector, driven by its focus on oncology and immunology. With a market capitalization of $2.52 billion and a profit margin of 77.5%, the company demonstrates strong financial performance. Key value drivers include the successful development and commercialization of its drug pipeline, particularly Fruquintinib and Savolitinib. Growth catalysts include potential regulatory approvals and expansion into new markets. However, investors may want to evaluate potential risks such as clinical trial failures and competition from other pharmaceutical companies. The company's strategic collaborations and focus on innovative therapies position it for long-term growth.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $2.52 billion reflects investor confidence in HUTCHMED's growth potential.
- Profit margin of 77.5% indicates strong operational efficiency and profitability.
- Gross margin of 8.9% demonstrates the company's ability to manage production costs effectively.
- Beta of 0.51 suggests lower volatility compared to the overall market, making it a potentially stable investment.
- Strategic collaborations with AstraZeneca and Lilly enhance HUTCHMED's drug development and commercialization capabilities.
Competitors & Peers
Strengths
- Strong pipeline of oncology and immunology drug candidates.
- Strategic collaborations with major pharmaceutical companies.
- Experienced management team with expertise in drug development.
- Established presence in the Chinese pharmaceutical market.
Weaknesses
- Reliance on clinical trial success and regulatory approvals.
- Competition from other pharmaceutical companies.
- Dependence on key partnerships for drug development and commercialization.
- Limited geographic diversification.
Catalysts
- Upcoming: Regulatory approvals for Fruquintinib in new indications.
- Upcoming: Clinical trial results for Savolitinib in NSCLC.
- Ongoing: Expansion of strategic collaborations with pharmaceutical companies.
- Ongoing: Advancement of immunotherapy pipeline through clinical trials.
Risks
- Potential: Clinical trial failures and regulatory setbacks.
- Potential: Competition from other pharmaceutical companies.
- Ongoing: Dependence on key partnerships for drug development and commercialization.
- Ongoing: Changes in healthcare regulations and reimbursement policies.
Growth Opportunities
- Expansion of Fruquintinib into New Indications: Fruquintinib, an inhibitor for CRC, breast cancer, GC, EMC, NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors, represents a significant growth opportunity for HUTCHMED. Expanding its use into additional indications beyond CRC could substantially increase its market reach and revenue potential. The global market for cancer therapeutics is projected to reach $200 billion by 2028, providing a substantial addressable market.
- Development and Commercialization of Savolitinib: Savolitinib, an inhibitor for NSCLC, papillary and renal cell carcinoma, CRC, and GC, is another key growth driver. Successful clinical trials and regulatory approvals for these indications could drive significant revenue growth. The NSCLC market alone is expected to reach $35 billion by 2027, offering a substantial opportunity for HUTCHMED.
- Strategic Collaborations and Partnerships: HUTCHMED's existing collaborations with AstraZeneca, Lilly, and BeiGene provide access to resources, expertise, and global markets. Forming new strategic partnerships with other pharmaceutical companies could further accelerate drug development and commercialization efforts. These partnerships can also provide access to new technologies and therapeutic areas.
- Expansion into New Geographic Markets: While HUTCHMED operates internationally, expanding its presence into new geographic markets, particularly in Europe and the United States, could drive significant growth. This expansion would require navigating regulatory processes and establishing commercial infrastructure, but the potential rewards are substantial. The global pharmaceutical market is expected to reach $1.5 trillion by 2026.
- Advancement of Immunotherapy Pipeline: HUTCHMED is developing several immunotherapies for cancer and immunological diseases. Advancing these drug candidates through clinical trials and securing regulatory approvals could create new revenue streams and diversify the company's product portfolio. The immunotherapy market is experiencing rapid growth, driven by the success of checkpoint inhibitors and other novel therapies.
Opportunities
- Expansion into new therapeutic areas and indications.
- Growth in the global oncology and immunology markets.
- Increased demand for targeted therapies and immunotherapies.
- Potential for new strategic partnerships and collaborations.
Threats
- Clinical trial failures and regulatory setbacks.
- Competition from generic drugs and biosimilars.
- Changes in healthcare regulations and reimbursement policies.
- Economic downturns and market volatility.
Competitive Advantages
- Proprietary drug pipeline with patented compounds.
- Strategic collaborations with major pharmaceutical companies.
- Expertise in oncology and immunology drug development.
- Established presence in the Chinese pharmaceutical market.
About HCM
HUTCHMED (China) Limited, formerly known as Hutchison China MediTech Limited, was incorporated in 2000 and is headquartered in Central, Hong Kong. The company is dedicated to the discovery, development, and commercialization of innovative therapeutics, particularly in oncology and immunology. HUTCHMED operates through two segments: Oncology/Immunology and Other Ventures. Its pipeline includes several drug candidates targeting various cancers, such as colorectal cancer (CRC), non-small cell lung cancer (NSCLC), gastric cancer (GC), and neuroendocrine tumors (NET). Key products under development include Savolitinib, Fruquintinib, and Surufatinib. HUTCHMED has established strategic collaborations with major pharmaceutical companies, including AstraZeneca, Lilly, and BeiGene, to accelerate the development and commercialization of its drug candidates. These collaborations provide HUTCHMED with access to resources, expertise, and global markets. The company's focus on targeted therapies and immunotherapies positions it to address unmet medical needs in cancer and immunological diseases. HUTCHMED's commitment to innovation and strategic partnerships underscores its mission to improve patient outcomes and create value for shareholders. As of 2026, HUTCHMED employs 1,811 individuals.
What They Do
- Discovers and develops targeted therapeutics for cancer and immunological diseases.
- Commercializes innovative drugs in Hong Kong and internationally.
- Focuses on oncology and immunology, addressing unmet medical needs.
- Develops inhibitors for various cancers, including colorectal cancer and lung cancer.
- Conducts clinical trials to evaluate the safety and efficacy of drug candidates.
- Establishes strategic collaborations with major pharmaceutical companies.
- Navigates regulatory approval processes to bring new drugs to market.
Business Model
- Develops and patents novel therapeutic drugs.
- Out-licenses or co-develops drugs with pharmaceutical partners.
- Generates revenue from drug sales and royalties.
- Invests in research and development to expand its drug pipeline.
Industry Context
HUTCHMED (China) Limited operates in the competitive pharmaceutical industry, specifically within the specialty and generic drug manufacturing segment. The global oncology market is experiencing significant growth, driven by increasing cancer prevalence and advancements in targeted therapies and immunotherapies. HUTCHMED's focus on these areas positions it to capitalize on these trends. The company competes with other pharmaceutical companies developing similar treatments, including ADPT, BHC, CDTX, CPRX, and IDYA. Success in this industry requires innovation, strategic partnerships, and effective navigation of regulatory processes.
Key Customers
- Patients with cancer and immunological diseases.
- Healthcare providers who prescribe HUTCHMED's drugs.
- Pharmaceutical companies that partner with HUTCHMED.
- Hospitals and clinics that use HUTCHMED's therapies.
Financials
Chart & Info
HUTCHMED (China) Limited (HCM) stock price: $13.37 (-0.28, -2.05%)
Latest News
-
Earnings Scheduled For March 5, 2026
benzinga · Mar 5, 2026
-
Earnings Scheduled For August 7, 2025
benzinga · Aug 7, 2025
-
Stocks That Hit 52-Week Lows On Monday
benzinga · Oct 24, 2022
-
Stocks That Hit 52-Week Lows On Tuesday
benzinga · Oct 11, 2022
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HCM.
Price Targets
Wall Street price target analysis for HCM.
MoonshotScore
What does this score mean?
The MoonshotScore rates HCM's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Chig Fung Cheng
Unknown
Information about Chig Fung Cheng's background is not available in the provided data. Therefore, a detailed biography cannot be provided. Further research would be needed to gather information about their career history, education, and previous roles.
Track Record: Information about Chig Fung Cheng's track record is not available in the provided data. Therefore, key achievements, strategic decisions, and company milestones under their leadership cannot be provided. Further research would be needed to gather this information.
HUTCHMED (China) Limited ADR Information Sponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. For HUTCHMED (China) Limited (HCM), each ADR represents a specific number of ordinary shares of the company traded on its home market. This allows U.S. investors to invest in HCM without the complexities of cross-border transactions.
- Home Market Ticker: Hong Kong Stock Exchange, Hong Kong
- ADR Level: 2
- ADR Ratio: 1:1
Common Questions About HCM
What does HUTCHMED (China) Limited do?
HUTCHMED (China) Limited is a biopharmaceutical company focused on discovering, developing, and commercializing targeted therapeutics and immunotherapies for cancer and immunological diseases. The company operates primarily in the Oncology/Immunology segment, developing treatments for various cancers such as colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and gastric cancer (GC). HUTCHMED collaborates with major pharmaceutical companies to accelerate drug development and commercialization, aiming to address unmet medical needs and improve patient outcomes.
What do analysts say about HCM stock?
Analyst consensus on HCM stock is not available in the provided data. However, key valuation metrics such as market capitalization ($2.52 billion) and profit margin (77.5%) provide insights into the company's financial health. Growth considerations include the successful development and commercialization of its drug pipeline, as well as potential regulatory approvals and expansion into new markets. Investors should conduct their own research and consider their individual risk tolerance before making any investment decisions.
What are the main risks for HCM?
The main risks for HUTCHMED (China) Limited include clinical trial failures and regulatory setbacks, which could delay or prevent the approval of its drug candidates. Competition from other pharmaceutical companies developing similar treatments also poses a risk. Additionally, the company's dependence on key partnerships for drug development and commercialization could be a vulnerability. Changes in healthcare regulations and reimbursement policies could also impact the company's profitability and growth prospects.
What are the key factors to evaluate for HCM?
HUTCHMED (China) Limited (HCM) currently holds an AI score of 42/100, indicating low score. Key strength: Strong pipeline of oncology and immunology drug candidates.. Primary risk to monitor: Potential: Clinical trial failures and regulatory setbacks.. This is not financial advice.
How frequently does HCM data refresh on this page?
HCM prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven HCM's recent stock price performance?
Recent price movement in HUTCHMED (China) Limited (HCM) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Strong pipeline of oncology and immunology drug candidates.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider HCM overvalued or undervalued right now?
Determining whether HUTCHMED (China) Limited (HCM) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying HCM?
Before investing in HUTCHMED (China) Limited (HCM), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on provided source data and may not be exhaustive.
- Analyst consensus and CEO track record are not available in the provided data.